Abbott has announced results from the FreeDM2 randomised controlled trial (RCT), indicating that improved glucose outcomes were observed in individuals using the FreeStyle Libre c ...

Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs).

At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. those using finger pricking1,2Improvements were participant-led, ...

About 3 million ‘Freestyle Libre 3 and 3 plus are being recalled because they can give dangerous false readings.

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. A major wrongful death lawsuit has been filed alleging ...

The US Food and Drug Administration has escalated the recall of specific Abbott FreeStyle Libre 3 and 3 Plus continuous glucose monitors to Class I, the highest level of urgency. The recall, which ...

Health care technology company Abbott has recalled certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitoring systems because the sensors are displaying incorrect glucose ...

(AP Photo/Jacquelyn Martin, File) (Jacquelyn Martin, Copyright 2018 The Associated Press. All rights reserved.) A voluntary recall has been issued for certain glucose ...

Abbott Diabetes Care has advised that certain glucose monitor sensors be removed from use or sale after the FDA classified the action as its most serious type of recall. The recall involves specific ...

Feb. 4 (UPI) --Officials for Abbott Diabetes Care have recalled some of the company's FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitor sensors for people with diabetes. The Food ...

Health care company Abbott is recalling its Freestyle Libre 3 and Libre 3 Plus glucose monitors, according to a news release. Abbott's ongoing product monitoring system reported that some of its ...